nodes	percent_of_prediction	percent_of_DWPC	metapath
Levonorgestrel—CYP19A1—Endogenous sterols—RXRA—thyroid cancer	0.00413	0.0144	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00404	0.0141	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TCF7L1—thyroid cancer	0.00384	0.0134	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear signaling by ERBB4—NRG1—thyroid cancer	0.00357	0.0125	CbGpPWpGaD
Levonorgestrel—SHBG—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.00345	0.0121	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00333	0.0116	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptors—RXRA—thyroid cancer	0.00321	0.0112	CbGpPWpGaD
Levonorgestrel—SHBG—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.00305	0.0106	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metapathway biotransformation—CHST14—thyroid cancer	0.0028	0.00977	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—MINPP1—thyroid cancer	0.00279	0.00976	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptors—PPARG—thyroid cancer	0.00266	0.0093	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00263	0.00918	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00254	0.00887	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptors—RXRA—thyroid cancer	0.00247	0.00864	CbGpPWpGaD
Levonorgestrel—AR—Regulation of Androgen receptor activity—RXRA—thyroid cancer	0.00246	0.0086	CbGpPWpGaD
Levonorgestrel—ESR1—FOXM1 transcription factor network—CDK1—thyroid cancer	0.00246	0.00859	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00244	0.00853	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—NDUFA13—thyroid cancer	0.00237	0.0083	CbGpPWpGaD
Levonorgestrel—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00235	0.0082	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—BRAF—thyroid cancer	0.00227	0.00794	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—CHST14—thyroid cancer	0.00223	0.0078	CbGpPWpGaD
Levonorgestrel—PGR—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.0021	0.00735	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear signaling by ERBB4—NRG1—thyroid cancer	0.0021	0.00732	CbGpPWpGaD
Levonorgestrel—AR—Nuclear Receptors—PPARG—thyroid cancer	0.00203	0.00708	CbGpPWpGaD
Levonorgestrel—AR—Notch-mediated HES/HEY network—HIF1A—thyroid cancer	0.00201	0.00703	CbGpPWpGaD
Levonorgestrel—ESR1—Nuclear Receptor transcription pathway—RXRA—thyroid cancer	0.00195	0.00683	CbGpPWpGaD
Levonorgestrel—CYP19A1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00192	0.0067	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—TRIM33—thyroid cancer	0.00187	0.00654	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—HPGD—thyroid cancer	0.0018	0.00629	CbGpPWpGaD
Levonorgestrel—Breast pain—Doxorubicin—thyroid cancer	0.0017	0.00242	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00169	0.00592	CbGpPWpGaD
Levonorgestrel—Amenorrhoea—Doxorubicin—thyroid cancer	0.00169	0.0024	CcSEcCtD
Levonorgestrel—Loss of consciousness—Sorafenib—thyroid cancer	0.00167	0.00237	CcSEcCtD
Levonorgestrel—Cough—Sorafenib—thyroid cancer	0.00166	0.00236	CcSEcCtD
Levonorgestrel—Asthenia—Vandetanib—thyroid cancer	0.00165	0.00234	CcSEcCtD
Levonorgestrel—Hypertension—Sorafenib—thyroid cancer	0.00164	0.00233	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CDK1—thyroid cancer	0.00163	0.00571	CbGpPWpGaD
Levonorgestrel—Pruritus—Vandetanib—thyroid cancer	0.00163	0.00231	CcSEcCtD
Levonorgestrel—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00163	0.00231	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00162	0.00567	CbGpPWpGaD
Levonorgestrel—Myalgia—Sorafenib—thyroid cancer	0.00162	0.0023	CcSEcCtD
Levonorgestrel—Herpes simplex—Doxorubicin—thyroid cancer	0.00161	0.00229	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00161	0.00228	CcSEcCtD
Levonorgestrel—AR—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.0016	0.0056	CbGpPWpGaD
Levonorgestrel—SRD5A1—head—thyroid cancer	0.00159	0.164	CbGeAlD
Levonorgestrel—Dermatitis contact—Epirubicin—thyroid cancer	0.00159	0.00226	CcSEcCtD
Levonorgestrel—Diarrhoea—Vandetanib—thyroid cancer	0.00157	0.00223	CcSEcCtD
Levonorgestrel—Cystitis noninfective—Epirubicin—thyroid cancer	0.00157	0.00223	CcSEcCtD
Levonorgestrel—ESR1—Nuclear Receptors—PPARG—thyroid cancer	0.00156	0.00546	CbGpPWpGaD
Levonorgestrel—Influenza like illness—Epirubicin—thyroid cancer	0.00156	0.00222	CcSEcCtD
Levonorgestrel—CYP19A1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00155	0.00543	CbGpPWpGaD
Levonorgestrel—Cystitis—Epirubicin—thyroid cancer	0.00155	0.0022	CcSEcCtD
Levonorgestrel—Infection—Sorafenib—thyroid cancer	0.00154	0.00219	CcSEcCtD
Levonorgestrel—Candida infection—Epirubicin—thyroid cancer	0.00153	0.00218	CcSEcCtD
Levonorgestrel—Shock—Sorafenib—thyroid cancer	0.00153	0.00217	CcSEcCtD
Levonorgestrel—Fluid retention—Epirubicin—thyroid cancer	0.00153	0.00217	CcSEcCtD
Levonorgestrel—Nervous system disorder—Sorafenib—thyroid cancer	0.00152	0.00216	CcSEcCtD
Levonorgestrel—Dizziness—Vandetanib—thyroid cancer	0.00152	0.00216	CcSEcCtD
Levonorgestrel—Vaginal infection—Epirubicin—thyroid cancer	0.00152	0.00215	CcSEcCtD
Levonorgestrel—Skin disorder—Sorafenib—thyroid cancer	0.00151	0.00214	CcSEcCtD
Levonorgestrel—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.0015	0.00214	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—CDK1—thyroid cancer	0.0015	0.00523	CbGpPWpGaD
Levonorgestrel—Anorexia—Sorafenib—thyroid cancer	0.00148	0.0021	CcSEcCtD
Levonorgestrel—Cramps of lower extremities—Epirubicin—thyroid cancer	0.00148	0.0021	CcSEcCtD
Levonorgestrel—Dermatitis contact—Doxorubicin—thyroid cancer	0.00147	0.00209	CcSEcCtD
Levonorgestrel—Vomiting—Vandetanib—thyroid cancer	0.00146	0.00208	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00146	0.0051	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.00146	0.00509	CbGpPWpGaD
Levonorgestrel—Neoplasm—Epirubicin—thyroid cancer	0.00145	0.00206	CcSEcCtD
Levonorgestrel—Bladder pain—Epirubicin—thyroid cancer	0.00145	0.00206	CcSEcCtD
Levonorgestrel—Cystitis noninfective—Doxorubicin—thyroid cancer	0.00145	0.00206	CcSEcCtD
Levonorgestrel—Rash—Vandetanib—thyroid cancer	0.00145	0.00206	CcSEcCtD
Levonorgestrel—Dermatitis—Vandetanib—thyroid cancer	0.00145	0.00206	CcSEcCtD
Levonorgestrel—Influenza like illness—Doxorubicin—thyroid cancer	0.00144	0.00205	CcSEcCtD
Levonorgestrel—Headache—Vandetanib—thyroid cancer	0.00144	0.00205	CcSEcCtD
Levonorgestrel—Cystitis—Doxorubicin—thyroid cancer	0.00144	0.00204	CcSEcCtD
Levonorgestrel—AR—Generic Transcription Pathway—TRIM33—thyroid cancer	0.00143	0.00499	CbGpPWpGaD
Levonorgestrel—Candida infection—Doxorubicin—thyroid cancer	0.00142	0.00202	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00141	0.00201	CcSEcCtD
Levonorgestrel—Fluid retention—Doxorubicin—thyroid cancer	0.00141	0.002	CcSEcCtD
Levonorgestrel—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.0014	0.0049	CbGpPWpGaD
Levonorgestrel—Vaginal infection—Doxorubicin—thyroid cancer	0.0014	0.00199	CcSEcCtD
Levonorgestrel—Abnormal vision—Epirubicin—thyroid cancer	0.0014	0.00199	CcSEcCtD
Levonorgestrel—Dyspnoea—Sorafenib—thyroid cancer	0.00138	0.00196	CcSEcCtD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—thyroid cancer	0.00137	0.0048	CbGpPWpGaD
Levonorgestrel—SHBG—neck—thyroid cancer	0.00137	0.141	CbGeAlD
Levonorgestrel—Nausea—Vandetanib—thyroid cancer	0.00137	0.00194	CcSEcCtD
Levonorgestrel—Cramps of lower extremities—Doxorubicin—thyroid cancer	0.00137	0.00194	CcSEcCtD
Levonorgestrel—Dyspepsia—Sorafenib—thyroid cancer	0.00137	0.00194	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—THRB—thyroid cancer	0.00135	0.00473	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Sorafenib—thyroid cancer	0.00135	0.00192	CcSEcCtD
Levonorgestrel—Bladder pain—Doxorubicin—thyroid cancer	0.00134	0.00191	CcSEcCtD
Levonorgestrel—Neoplasm—Doxorubicin—thyroid cancer	0.00134	0.00191	CcSEcCtD
Levonorgestrel—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00134	0.0019	CcSEcCtD
Levonorgestrel—Fatigue—Sorafenib—thyroid cancer	0.00134	0.0019	CcSEcCtD
Levonorgestrel—Constipation—Sorafenib—thyroid cancer	0.00133	0.00188	CcSEcCtD
Levonorgestrel—Pain—Sorafenib—thyroid cancer	0.00133	0.00188	CcSEcCtD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—thyroid cancer	0.00131	0.00458	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.0013	0.00456	CbGpPWpGaD
Levonorgestrel—Vascular purpura—Epirubicin—thyroid cancer	0.0013	0.00185	CcSEcCtD
Levonorgestrel—Eczema—Epirubicin—thyroid cancer	0.0013	0.00184	CcSEcCtD
Levonorgestrel—Abnormal vision—Doxorubicin—thyroid cancer	0.0013	0.00184	CcSEcCtD
Levonorgestrel—AR—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00128	0.00448	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00127	0.0018	CcSEcCtD
Levonorgestrel—PGR—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.00125	0.00435	CbGpPWpGaD
Levonorgestrel—Increased appetite—Epirubicin—thyroid cancer	0.00124	0.00176	CcSEcCtD
Levonorgestrel—ESR1—Nuclear Receptor transcription pathway—PPARG—thyroid cancer	0.00123	0.00431	CbGpPWpGaD
Levonorgestrel—Urticaria—Sorafenib—thyroid cancer	0.00123	0.00175	CcSEcCtD
Levonorgestrel—Abdominal pain—Sorafenib—thyroid cancer	0.00123	0.00174	CcSEcCtD
Levonorgestrel—Body temperature increased—Sorafenib—thyroid cancer	0.00123	0.00174	CcSEcCtD
Levonorgestrel—Purpura—Epirubicin—thyroid cancer	0.00121	0.00172	CcSEcCtD
Levonorgestrel—Vascular purpura—Doxorubicin—thyroid cancer	0.00121	0.00171	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—TERT—thyroid cancer	0.00121	0.00421	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—NRG1—thyroid cancer	0.0012	0.0042	CbGpPWpGaD
Levonorgestrel—Eczema—Doxorubicin—thyroid cancer	0.0012	0.00171	CcSEcCtD
Levonorgestrel—Pain in extremity—Epirubicin—thyroid cancer	0.00117	0.00166	CcSEcCtD
Levonorgestrel—Increased appetite—Doxorubicin—thyroid cancer	0.00115	0.00163	CcSEcCtD
Levonorgestrel—Migraine—Epirubicin—thyroid cancer	0.00115	0.00163	CcSEcCtD
Levonorgestrel—Affect lability—Epirubicin—thyroid cancer	0.00115	0.00163	CcSEcCtD
Levonorgestrel—Hypersensitivity—Sorafenib—thyroid cancer	0.00114	0.00162	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—HIF1A—thyroid cancer	0.00113	0.00394	CbGpPWpGaD
Levonorgestrel—Purpura—Doxorubicin—thyroid cancer	0.00112	0.00159	CcSEcCtD
Levonorgestrel—Asthenia—Sorafenib—thyroid cancer	0.00111	0.00158	CcSEcCtD
Levonorgestrel—Mood swings—Epirubicin—thyroid cancer	0.00111	0.00157	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—TRIM33—thyroid cancer	0.0011	0.00384	CbGpPWpGaD
Levonorgestrel—Pruritus—Sorafenib—thyroid cancer	0.0011	0.00156	CcSEcCtD
Levonorgestrel—Pain in extremity—Doxorubicin—thyroid cancer	0.00108	0.00153	CcSEcCtD
Levonorgestrel—Dry skin—Epirubicin—thyroid cancer	0.00107	0.00152	CcSEcCtD
Levonorgestrel—AR—Nongenotropic Androgen signaling—HRAS—thyroid cancer	0.00107	0.00373	CbGpPWpGaD
Levonorgestrel—Affect lability—Doxorubicin—thyroid cancer	0.00106	0.00151	CcSEcCtD
Levonorgestrel—Migraine—Doxorubicin—thyroid cancer	0.00106	0.00151	CcSEcCtD
Levonorgestrel—Diarrhoea—Sorafenib—thyroid cancer	0.00106	0.00151	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.00105	0.00368	CbGpPWpGaD
Levonorgestrel—Breast disorder—Epirubicin—thyroid cancer	0.00105	0.0015	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—TPR—thyroid cancer	0.00103	0.00361	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—THRB—thyroid cancer	0.00103	0.0036	CbGpPWpGaD
Levonorgestrel—Dizziness—Sorafenib—thyroid cancer	0.00103	0.00146	CcSEcCtD
Levonorgestrel—ESR1—FOXM1 transcription factor network—CCND1—thyroid cancer	0.00102	0.00358	CbGpPWpGaD
Levonorgestrel—Mood swings—Doxorubicin—thyroid cancer	0.00102	0.00145	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism—PRKAR1A—thyroid cancer	0.00102	0.00355	CbGpPWpGaD
Levonorgestrel—Abdominal distension—Epirubicin—thyroid cancer	0.00101	0.00144	CcSEcCtD
Levonorgestrel—Asthma—Epirubicin—thyroid cancer	0.00101	0.00143	CcSEcCtD
Levonorgestrel—Influenza—Epirubicin—thyroid cancer	0.00101	0.00143	CcSEcCtD
Levonorgestrel—Dry skin—Doxorubicin—thyroid cancer	0.000989	0.00141	CcSEcCtD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—CCND1—thyroid cancer	0.000987	0.00345	CbGpPWpGaD
Levonorgestrel—Vomiting—Sorafenib—thyroid cancer	0.000986	0.0014	CcSEcCtD
Levonorgestrel—Rash—Sorafenib—thyroid cancer	0.000978	0.00139	CcSEcCtD
Levonorgestrel—Dermatitis—Sorafenib—thyroid cancer	0.000977	0.00139	CcSEcCtD
Levonorgestrel—Breast disorder—Doxorubicin—thyroid cancer	0.000975	0.00139	CcSEcCtD
Levonorgestrel—Headache—Sorafenib—thyroid cancer	0.000972	0.00138	CcSEcCtD
Levonorgestrel—Bronchitis—Epirubicin—thyroid cancer	0.00097	0.00138	CcSEcCtD
Levonorgestrel—ESR1—neck—thyroid cancer	0.000967	0.0995	CbGeAlD
Levonorgestrel—AR—Nongenotropic Androgen signaling—AKT1—thyroid cancer	0.000943	0.0033	CbGpPWpGaD
Levonorgestrel—Dysuria—Epirubicin—thyroid cancer	0.000943	0.00134	CcSEcCtD
Levonorgestrel—Abdominal distension—Doxorubicin—thyroid cancer	0.000939	0.00133	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000937	0.00133	CcSEcCtD
Levonorgestrel—Influenza—Doxorubicin—thyroid cancer	0.000933	0.00132	CcSEcCtD
Levonorgestrel—Asthma—Doxorubicin—thyroid cancer	0.000933	0.00132	CcSEcCtD
Levonorgestrel—Pollakiuria—Epirubicin—thyroid cancer	0.000931	0.00132	CcSEcCtD
Levonorgestrel—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000925	0.00323	CbGpPWpGaD
Levonorgestrel—ESR1—Estrogen signaling pathway—AKT1—thyroid cancer	0.000923	0.00322	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000922	0.00322	CbGpPWpGaD
Levonorgestrel—Nausea—Sorafenib—thyroid cancer	0.000921	0.00131	CcSEcCtD
Levonorgestrel—Weight increased—Epirubicin—thyroid cancer	0.000918	0.0013	CcSEcCtD
Levonorgestrel—Weight decreased—Epirubicin—thyroid cancer	0.000912	0.0013	CcSEcCtD
Levonorgestrel—CYP19A1—FSH signaling pathway—AKT1—thyroid cancer	0.000907	0.00317	CbGpPWpGaD
Levonorgestrel—Pneumonia—Epirubicin—thyroid cancer	0.000904	0.00128	CcSEcCtD
Levonorgestrel—PGR—Gene Expression—TRIM33—thyroid cancer	0.000902	0.00315	CbGpPWpGaD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—NRAS—thyroid cancer	0.000899	0.00314	CbGpPWpGaD
Levonorgestrel—Infestation NOS—Epirubicin—thyroid cancer	0.000899	0.00128	CcSEcCtD
Levonorgestrel—Infestation—Epirubicin—thyroid cancer	0.000899	0.00128	CcSEcCtD
Levonorgestrel—Bronchitis—Doxorubicin—thyroid cancer	0.000897	0.00127	CcSEcCtD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000882	0.00308	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—CDK1—thyroid cancer	0.000879	0.00307	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000878	0.00307	CbGpPWpGaD
Levonorgestrel—Urinary tract infection—Epirubicin—thyroid cancer	0.000874	0.00124	CcSEcCtD
Levonorgestrel—Dysuria—Doxorubicin—thyroid cancer	0.000872	0.00124	CcSEcCtD
Levonorgestrel—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000867	0.00123	CcSEcCtD
Levonorgestrel—Pollakiuria—Doxorubicin—thyroid cancer	0.000862	0.00122	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—MEN1—thyroid cancer	0.00086	0.003	CbGpPWpGaD
Levonorgestrel—Weight increased—Doxorubicin—thyroid cancer	0.000849	0.00121	CcSEcCtD
Levonorgestrel—Weight decreased—Doxorubicin—thyroid cancer	0.000844	0.0012	CcSEcCtD
Levonorgestrel—Sinusitis—Epirubicin—thyroid cancer	0.000843	0.0012	CcSEcCtD
Levonorgestrel—Pneumonia—Doxorubicin—thyroid cancer	0.000837	0.00119	CcSEcCtD
Levonorgestrel—Infestation—Doxorubicin—thyroid cancer	0.000832	0.00118	CcSEcCtD
Levonorgestrel—Infestation NOS—Doxorubicin—thyroid cancer	0.000832	0.00118	CcSEcCtD
Levonorgestrel—CYP19A1—Biological oxidations—RXRA—thyroid cancer	0.000826	0.00288	CbGpPWpGaD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00082	0.00287	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000816	0.00285	CbGpPWpGaD
Levonorgestrel—Haemoglobin—Epirubicin—thyroid cancer	0.000811	0.00115	CcSEcCtD
Levonorgestrel—Rhinitis—Epirubicin—thyroid cancer	0.000809	0.00115	CcSEcCtD
Levonorgestrel—Urinary tract infection—Doxorubicin—thyroid cancer	0.000809	0.00115	CcSEcCtD
Levonorgestrel—Haemorrhage—Epirubicin—thyroid cancer	0.000807	0.00115	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Epirubicin—thyroid cancer	0.000803	0.00114	CcSEcCtD
Levonorgestrel—Pharyngitis—Epirubicin—thyroid cancer	0.000801	0.00114	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Epirubicin—thyroid cancer	0.000797	0.00113	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—THRB—thyroid cancer	0.000795	0.00278	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—thyroid cancer	0.000794	0.00278	CbGpPWpGaD
Levonorgestrel—Connective tissue disorder—Epirubicin—thyroid cancer	0.000793	0.00113	CcSEcCtD
Levonorgestrel—Urethral disorder—Epirubicin—thyroid cancer	0.000791	0.00112	CcSEcCtD
Levonorgestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000781	0.00273	CbGpPWpGaD
Levonorgestrel—ESR1—ATF-2 transcription factor network—CCND1—thyroid cancer	0.000781	0.00273	CbGpPWpGaD
Levonorgestrel—Sinusitis—Doxorubicin—thyroid cancer	0.00078	0.00111	CcSEcCtD
Levonorgestrel—Visual impairment—Epirubicin—thyroid cancer	0.000778	0.0011	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—KRAS—thyroid cancer	0.000774	0.0027	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—SLC5A5—thyroid cancer	0.000774	0.0027	CbGpPWpGaD
Levonorgestrel—AR—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.00077	0.00269	CbGpPWpGaD
Levonorgestrel—Erythema multiforme—Epirubicin—thyroid cancer	0.000763	0.00108	CcSEcCtD
Levonorgestrel—Eye disorder—Epirubicin—thyroid cancer	0.000754	0.00107	CcSEcCtD
Levonorgestrel—Haemoglobin—Doxorubicin—thyroid cancer	0.00075	0.00107	CcSEcCtD
Levonorgestrel—Cardiac disorder—Epirubicin—thyroid cancer	0.000749	0.00106	CcSEcCtD
Levonorgestrel—Rhinitis—Doxorubicin—thyroid cancer	0.000749	0.00106	CcSEcCtD
Levonorgestrel—Haemorrhage—Doxorubicin—thyroid cancer	0.000747	0.00106	CcSEcCtD
Levonorgestrel—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000743	0.00106	CcSEcCtD
Levonorgestrel—Pharyngitis—Doxorubicin—thyroid cancer	0.000741	0.00105	CcSEcCtD
Levonorgestrel—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000737	0.00105	CcSEcCtD
Levonorgestrel—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000734	0.00104	CcSEcCtD
Levonorgestrel—Urethral disorder—Doxorubicin—thyroid cancer	0.000732	0.00104	CcSEcCtD
Levonorgestrel—ESR1—Validated nuclear estrogen receptor alpha network—CCND1—thyroid cancer	0.000732	0.00256	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—CCND1—thyroid cancer	0.000729	0.00255	CbGpPWpGaD
Levonorgestrel—Immune system disorder—Epirubicin—thyroid cancer	0.000729	0.00104	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Epirubicin—thyroid cancer	0.000727	0.00103	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000725	0.00253	CbGpPWpGaD
Levonorgestrel—Arrhythmia—Epirubicin—thyroid cancer	0.000721	0.00102	CcSEcCtD
Levonorgestrel—Visual impairment—Doxorubicin—thyroid cancer	0.00072	0.00102	CcSEcCtD
Levonorgestrel—Alopecia—Epirubicin—thyroid cancer	0.000713	0.00101	CcSEcCtD
Levonorgestrel—Mental disorder—Epirubicin—thyroid cancer	0.000707	0.001	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000706	0.00247	CbGpPWpGaD
Levonorgestrel—Erythema multiforme—Doxorubicin—thyroid cancer	0.000706	0.001	CcSEcCtD
Levonorgestrel—ESR1—Signaling by ERBB4—NRG1—thyroid cancer	0.000706	0.00247	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—PTEN—thyroid cancer	0.000704	0.00246	CbGpPWpGaD
Levonorgestrel—Erythema—Epirubicin—thyroid cancer	0.000702	0.000998	CcSEcCtD
Levonorgestrel—Malnutrition—Epirubicin—thyroid cancer	0.000702	0.000998	CcSEcCtD
Levonorgestrel—Eye disorder—Doxorubicin—thyroid cancer	0.000698	0.000991	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—CCND1—thyroid cancer	0.000697	0.00243	CbGpPWpGaD
Levonorgestrel—Cardiac disorder—Doxorubicin—thyroid cancer	0.000693	0.000984	CcSEcCtD
Levonorgestrel—Flatulence—Epirubicin—thyroid cancer	0.000692	0.000983	CcSEcCtD
Levonorgestrel—Tension—Epirubicin—thyroid cancer	0.000689	0.000979	CcSEcCtD
Levonorgestrel—AR—Gene Expression—TRIM33—thyroid cancer	0.000687	0.0024	CbGpPWpGaD
Levonorgestrel—Nervousness—Epirubicin—thyroid cancer	0.000682	0.000969	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—CCND1—thyroid cancer	0.000681	0.00238	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.00068	0.00237	CbGpPWpGaD
Levonorgestrel—Back pain—Epirubicin—thyroid cancer	0.00068	0.000965	CcSEcCtD
Levonorgestrel—Muscle spasms—Epirubicin—thyroid cancer	0.000675	0.000959	CcSEcCtD
Levonorgestrel—Immune system disorder—Doxorubicin—thyroid cancer	0.000674	0.000958	CcSEcCtD
Levonorgestrel—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000673	0.000956	CcSEcCtD
Levonorgestrel—Arrhythmia—Doxorubicin—thyroid cancer	0.000667	0.000947	CcSEcCtD
Levonorgestrel—ESR1—LKB1 signaling events—TP53—thyroid cancer	0.000662	0.00231	CbGpPWpGaD
Levonorgestrel—Alopecia—Doxorubicin—thyroid cancer	0.00066	0.000937	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—HRAS—thyroid cancer	0.000658	0.0023	CbGpPWpGaD
Levonorgestrel—ESR1—AP-1 transcription factor network—PTEN—thyroid cancer	0.000657	0.0023	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—MEN1—thyroid cancer	0.000655	0.00229	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000655	0.00229	CbGpPWpGaD
Levonorgestrel—Mental disorder—Doxorubicin—thyroid cancer	0.000654	0.000929	CcSEcCtD
Levonorgestrel—SHBG—thyroid gland—thyroid cancer	0.000654	0.0672	CbGeAlD
Levonorgestrel—PGR—Gene Expression—THRB—thyroid cancer	0.000652	0.00228	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—RXRA—thyroid cancer	0.00065	0.00227	CbGpPWpGaD
Levonorgestrel—Malnutrition—Doxorubicin—thyroid cancer	0.00065	0.000923	CcSEcCtD
Levonorgestrel—Erythema—Doxorubicin—thyroid cancer	0.00065	0.000923	CcSEcCtD
Levonorgestrel—Anaemia—Epirubicin—thyroid cancer	0.000649	0.000922	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—CCND1—thyroid cancer	0.000644	0.00225	CbGpPWpGaD
Levonorgestrel—Flatulence—Doxorubicin—thyroid cancer	0.000641	0.00091	CcSEcCtD
Levonorgestrel—Tension—Doxorubicin—thyroid cancer	0.000638	0.000906	CcSEcCtD
Levonorgestrel—SRD5A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000632	0.00221	CbGpPWpGaD
Levonorgestrel—Nervousness—Doxorubicin—thyroid cancer	0.000631	0.000897	CcSEcCtD
Levonorgestrel—Vertigo—Epirubicin—thyroid cancer	0.000631	0.000896	CcSEcCtD
Levonorgestrel—Syncope—Epirubicin—thyroid cancer	0.00063	0.000895	CcSEcCtD
Levonorgestrel—Back pain—Doxorubicin—thyroid cancer	0.000629	0.000893	CcSEcCtD
Levonorgestrel—Muscle spasms—Doxorubicin—thyroid cancer	0.000625	0.000888	CcSEcCtD
Levonorgestrel—Palpitations—Epirubicin—thyroid cancer	0.000621	0.000882	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—CALCB—thyroid cancer	0.000618	0.00216	CbGpPWpGaD
Levonorgestrel—Loss of consciousness—Epirubicin—thyroid cancer	0.000617	0.000877	CcSEcCtD
Levonorgestrel—Cough—Epirubicin—thyroid cancer	0.000613	0.000871	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—MINPP1—thyroid cancer	0.000607	0.00212	CbGpPWpGaD
Levonorgestrel—Hypertension—Epirubicin—thyroid cancer	0.000607	0.000861	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—PTEN—thyroid cancer	0.000602	0.0021	CbGpPWpGaD
Levonorgestrel—Anaemia—Doxorubicin—thyroid cancer	0.000601	0.000853	CcSEcCtD
Levonorgestrel—ESR1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.0006	0.0021	CbGpPWpGaD
Levonorgestrel—Chest pain—Epirubicin—thyroid cancer	0.000598	0.000849	CcSEcCtD
Levonorgestrel—Myalgia—Epirubicin—thyroid cancer	0.000598	0.000849	CcSEcCtD
Levonorgestrel—Anxiety—Epirubicin—thyroid cancer	0.000596	0.000847	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000594	0.000844	CcSEcCtD
Levonorgestrel—Discomfort—Epirubicin—thyroid cancer	0.000591	0.000839	CcSEcCtD
Levonorgestrel—PGR—thyroid gland—thyroid cancer	0.000589	0.0606	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—TRIM33—thyroid cancer	0.000586	0.00205	CbGpPWpGaD
Levonorgestrel—Vertigo—Doxorubicin—thyroid cancer	0.000584	0.000829	CcSEcCtD
Levonorgestrel—Syncope—Doxorubicin—thyroid cancer	0.000583	0.000828	CcSEcCtD
Levonorgestrel—ESR1—Plasma membrane estrogen receptor signaling—AKT1—thyroid cancer	0.000581	0.00203	CbGpPWpGaD
Levonorgestrel—PGR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000575	0.00201	CbGpPWpGaD
Levonorgestrel—Palpitations—Doxorubicin—thyroid cancer	0.000574	0.000816	CcSEcCtD
Levonorgestrel—Oedema—Epirubicin—thyroid cancer	0.000573	0.000814	CcSEcCtD
Levonorgestrel—Loss of consciousness—Doxorubicin—thyroid cancer	0.000571	0.000811	CcSEcCtD
Levonorgestrel—Infection—Epirubicin—thyroid cancer	0.00057	0.000809	CcSEcCtD
Levonorgestrel—Cough—Doxorubicin—thyroid cancer	0.000567	0.000806	CcSEcCtD
Levonorgestrel—Shock—Epirubicin—thyroid cancer	0.000564	0.000801	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000563	0.00197	CbGpPWpGaD
Levonorgestrel—Nervous system disorder—Epirubicin—thyroid cancer	0.000562	0.000799	CcSEcCtD
Levonorgestrel—Hypertension—Doxorubicin—thyroid cancer	0.000561	0.000797	CcSEcCtD
Levonorgestrel—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000559	0.00195	CbGpPWpGaD
Levonorgestrel—Skin disorder—Epirubicin—thyroid cancer	0.000557	0.000791	CcSEcCtD
Levonorgestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000556	0.00194	CbGpPWpGaD
Levonorgestrel—Hyperhidrosis—Epirubicin—thyroid cancer	0.000554	0.000787	CcSEcCtD
Levonorgestrel—Myalgia—Doxorubicin—thyroid cancer	0.000553	0.000786	CcSEcCtD
Levonorgestrel—Chest pain—Doxorubicin—thyroid cancer	0.000553	0.000786	CcSEcCtD
Levonorgestrel—Anxiety—Doxorubicin—thyroid cancer	0.000551	0.000783	CcSEcCtD
Levonorgestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00055	0.000781	CcSEcCtD
Levonorgestrel—AR—Coregulation of Androgen receptor activity—AKT1—thyroid cancer	0.000549	0.00192	CbGpPWpGaD
Levonorgestrel—Discomfort—Doxorubicin—thyroid cancer	0.000547	0.000777	CcSEcCtD
Levonorgestrel—Anorexia—Epirubicin—thyroid cancer	0.000547	0.000776	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—NRAS—thyroid cancer	0.000537	0.00188	CbGpPWpGaD
Levonorgestrel—Oedema—Doxorubicin—thyroid cancer	0.00053	0.000753	CcSEcCtD
Levonorgestrel—CYP19A1—thyroid gland—thyroid cancer	0.00053	0.0545	CbGeAlD
Levonorgestrel—ESR1—Gene Expression—TRIM33—thyroid cancer	0.000529	0.00185	CbGpPWpGaD
Levonorgestrel—Infection—Doxorubicin—thyroid cancer	0.000527	0.000749	CcSEcCtD
Levonorgestrel—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000522	0.000742	CcSEcCtD
Levonorgestrel—PGR—head—thyroid cancer	0.000522	0.0537	CbGeAlD
Levonorgestrel—Shock—Doxorubicin—thyroid cancer	0.000522	0.000741	CcSEcCtD
Levonorgestrel—Nervous system disorder—Doxorubicin—thyroid cancer	0.00052	0.000739	CcSEcCtD
Levonorgestrel—Insomnia—Epirubicin—thyroid cancer	0.000519	0.000737	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—NDUFA13—thyroid cancer	0.000516	0.0018	CbGpPWpGaD
Levonorgestrel—Skin disorder—Doxorubicin—thyroid cancer	0.000515	0.000732	CcSEcCtD
Levonorgestrel—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000513	0.000728	CcSEcCtD
Levonorgestrel—Dyspnoea—Epirubicin—thyroid cancer	0.000511	0.000726	CcSEcCtD
Levonorgestrel—Somnolence—Epirubicin—thyroid cancer	0.00051	0.000724	CcSEcCtD
Levonorgestrel—Anorexia—Doxorubicin—thyroid cancer	0.000506	0.000718	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—MEN1—thyroid cancer	0.000505	0.00176	CbGpPWpGaD
Levonorgestrel—Dyspepsia—Epirubicin—thyroid cancer	0.000505	0.000717	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000504	0.00176	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Epirubicin—thyroid cancer	0.000498	0.000708	CcSEcCtD
Levonorgestrel—AR—Gene Expression—THRB—thyroid cancer	0.000497	0.00174	CbGpPWpGaD
Levonorgestrel—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000495	0.000703	CcSEcCtD
Levonorgestrel—Fatigue—Epirubicin—thyroid cancer	0.000494	0.000702	CcSEcCtD
Levonorgestrel—Pain—Epirubicin—thyroid cancer	0.00049	0.000696	CcSEcCtD
Levonorgestrel—Constipation—Epirubicin—thyroid cancer	0.00049	0.000696	CcSEcCtD
Levonorgestrel—CYP19A1—Metabolism—CHST14—thyroid cancer	0.000485	0.00169	CbGpPWpGaD
Levonorgestrel—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000483	0.000686	CcSEcCtD
Levonorgestrel—Insomnia—Doxorubicin—thyroid cancer	0.00048	0.000681	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000478	0.00167	CbGpPWpGaD
Levonorgestrel—Dyspnoea—Doxorubicin—thyroid cancer	0.000473	0.000672	CcSEcCtD
Levonorgestrel—Somnolence—Doxorubicin—thyroid cancer	0.000472	0.00067	CcSEcCtD
Levonorgestrel—CYP19A1—head—thyroid cancer	0.00047	0.0483	CbGeAlD
Levonorgestrel—AR—thyroid gland—thyroid cancer	0.000469	0.0482	CbGeAlD
Levonorgestrel—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000469	0.000666	CcSEcCtD
Levonorgestrel—Dyspepsia—Doxorubicin—thyroid cancer	0.000467	0.000663	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—KRAS—thyroid cancer	0.000462	0.00162	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000461	0.00161	CbGpPWpGaD
Levonorgestrel—Decreased appetite—Doxorubicin—thyroid cancer	0.000461	0.000655	CcSEcCtD
Levonorgestrel—ESR1—thyroid gland—thyroid cancer	0.00046	0.0474	CbGeAlD
Levonorgestrel—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000458	0.00065	CcSEcCtD
Levonorgestrel—Fatigue—Doxorubicin—thyroid cancer	0.000457	0.00065	CcSEcCtD
Levonorgestrel—Urticaria—Epirubicin—thyroid cancer	0.000455	0.000647	CcSEcCtD
Levonorgestrel—Constipation—Doxorubicin—thyroid cancer	0.000454	0.000644	CcSEcCtD
Levonorgestrel—Pain—Doxorubicin—thyroid cancer	0.000454	0.000644	CcSEcCtD
Levonorgestrel—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000454	0.00158	CbGpPWpGaD
Levonorgestrel—Body temperature increased—Epirubicin—thyroid cancer	0.000453	0.000644	CcSEcCtD
Levonorgestrel—Abdominal pain—Epirubicin—thyroid cancer	0.000453	0.000644	CcSEcCtD
Levonorgestrel—ESR1—AP-1 transcription factor network—TP53—thyroid cancer	0.000449	0.00157	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—TPR—thyroid cancer	0.00044	0.00154	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—RXRA—thyroid cancer	0.000438	0.00153	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000438	0.00153	CbGpPWpGaD
Levonorgestrel—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000437	0.00153	CbGpPWpGaD
Levonorgestrel—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000434	0.000616	CcSEcCtD
Levonorgestrel—Hypersensitivity—Epirubicin—thyroid cancer	0.000422	0.0006	CcSEcCtD
Levonorgestrel—Urticaria—Doxorubicin—thyroid cancer	0.000421	0.000599	CcSEcCtD
Levonorgestrel—Abdominal pain—Doxorubicin—thyroid cancer	0.000419	0.000596	CcSEcCtD
Levonorgestrel—Body temperature increased—Doxorubicin—thyroid cancer	0.000419	0.000596	CcSEcCtD
Levonorgestrel—AR—head—thyroid cancer	0.000416	0.0428	CbGeAlD
Levonorgestrel—PGR—Gene Expression—MEN1—thyroid cancer	0.000414	0.00145	CbGpPWpGaD
Levonorgestrel—Asthenia—Epirubicin—thyroid cancer	0.000411	0.000584	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000411	0.00144	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PPARG—thyroid cancer	0.00041	0.00143	CbGpPWpGaD
Levonorgestrel—ESR1—head—thyroid cancer	0.000409	0.042	CbGeAlD
Levonorgestrel—ESR1—Leptin signaling pathway—HRAS—thyroid cancer	0.000406	0.00142	CbGpPWpGaD
Levonorgestrel—AR—Androgen receptor signaling pathway—AKT1—thyroid cancer	0.000406	0.00142	CbGpPWpGaD
Levonorgestrel—Pruritus—Epirubicin—thyroid cancer	0.000406	0.000576	CcSEcCtD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000397	0.00139	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000396	0.00138	CbGpPWpGaD
Levonorgestrel—PGR—Signaling by ERBB4—HRAS—thyroid cancer	0.000393	0.00137	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Epirubicin—thyroid cancer	0.000392	0.000557	CcSEcCtD
Levonorgestrel—PGR—Signaling Pathways—TCF7L1—thyroid cancer	0.000391	0.00137	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—HPGD—thyroid cancer	0.000391	0.00137	CbGpPWpGaD
Levonorgestrel—Hypersensitivity—Doxorubicin—thyroid cancer	0.000391	0.000555	CcSEcCtD
Levonorgestrel—ESR1—Regulation of Telomerase—AKT1—thyroid cancer	0.000388	0.00135	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—THRB—thyroid cancer	0.000383	0.00134	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000382	0.00134	CbGpPWpGaD
Levonorgestrel—Asthenia—Doxorubicin—thyroid cancer	0.000381	0.000541	CcSEcCtD
Levonorgestrel—Dizziness—Epirubicin—thyroid cancer	0.000379	0.000538	CcSEcCtD
Levonorgestrel—Pruritus—Doxorubicin—thyroid cancer	0.000375	0.000533	CcSEcCtD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000368	0.00129	CbGpPWpGaD
Levonorgestrel—PGR—lymph node—thyroid cancer	0.000366	0.0376	CbGeAlD
Levonorgestrel—Vomiting—Epirubicin—thyroid cancer	0.000365	0.000518	CcSEcCtD
Levonorgestrel—PGR—Generic Transcription Pathway—PPARG—thyroid cancer	0.000363	0.00127	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CALCB—thyroid cancer	0.000363	0.00127	CbGpPWpGaD
Levonorgestrel—Diarrhoea—Doxorubicin—thyroid cancer	0.000363	0.000516	CcSEcCtD
Levonorgestrel—Rash—Epirubicin—thyroid cancer	0.000361	0.000513	CcSEcCtD
Levonorgestrel—Dermatitis—Epirubicin—thyroid cancer	0.000361	0.000513	CcSEcCtD
Levonorgestrel—Headache—Epirubicin—thyroid cancer	0.000359	0.00051	CcSEcCtD
Levonorgestrel—ESR1—Leptin signaling pathway—AKT1—thyroid cancer	0.000358	0.00125	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.000355	0.00124	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000354	0.00124	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—PTEN—thyroid cancer	0.000353	0.00123	CbGpPWpGaD
Levonorgestrel—Dizziness—Doxorubicin—thyroid cancer	0.000351	0.000498	CcSEcCtD
Levonorgestrel—PGR—Signaling by ERBB4—AKT1—thyroid cancer	0.000347	0.00121	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TRIM33—thyroid cancer	0.000344	0.0012	CbGpPWpGaD
Levonorgestrel—Nausea—Epirubicin—thyroid cancer	0.000341	0.000484	CcSEcCtD
Levonorgestrel—ESR1—Generic Transcription Pathway—RXRA—thyroid cancer	0.000338	0.00118	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000338	0.00118	CbGpPWpGaD
Levonorgestrel—Vomiting—Doxorubicin—thyroid cancer	0.000337	0.000479	CcSEcCtD
Levonorgestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—thyroid cancer	0.000337	0.00118	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—TPR—thyroid cancer	0.000336	0.00117	CbGpPWpGaD
Levonorgestrel—Rash—Doxorubicin—thyroid cancer	0.000334	0.000475	CcSEcCtD
Levonorgestrel—Dermatitis—Doxorubicin—thyroid cancer	0.000334	0.000475	CcSEcCtD
Levonorgestrel—Headache—Doxorubicin—thyroid cancer	0.000332	0.000472	CcSEcCtD
Levonorgestrel—CYP19A1—lymph node—thyroid cancer	0.000329	0.0339	CbGeAlD
Levonorgestrel—SRD5A1—Metabolism—PTGS2—thyroid cancer	0.000323	0.00113	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000317	0.00111	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—MEN1—thyroid cancer	0.000315	0.0011	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—NRAS—thyroid cancer	0.000315	0.0011	CbGpPWpGaD
Levonorgestrel—Nausea—Doxorubicin—thyroid cancer	0.000315	0.000448	CcSEcCtD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000315	0.0011	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000305	0.00107	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000305	0.00106	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000294	0.00103	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000293	0.00103	CbGpPWpGaD
Levonorgestrel—AR—lymph node—thyroid cancer	0.000291	0.03	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—TSHR—thyroid cancer	0.000286	0.001	CbGpPWpGaD
Levonorgestrel—ESR1—lymph node—thyroid cancer	0.000286	0.0294	CbGeAlD
Levonorgestrel—PGR—Signaling Pathways—PRKAR1A—thyroid cancer	0.000282	0.000984	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—PTEN—thyroid cancer	0.000282	0.000984	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—RXRA—thyroid cancer	0.000277	0.000968	CbGpPWpGaD
Levonorgestrel—AR—Generic Transcription Pathway—PPARG—thyroid cancer	0.000277	0.000967	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	0.000273	0.000953	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—KRAS—thyroid cancer	0.000271	0.000948	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000271	0.000946	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—MEN1—thyroid cancer	0.000269	0.000941	CbGpPWpGaD
Levonorgestrel—AR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000266	0.000929	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000261	0.000911	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—TPR—thyroid cancer	0.000258	0.000903	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTCH1—thyroid cancer	0.000243	0.000851	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—MEN1—thyroid cancer	0.000243	0.000849	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—TP53—thyroid cancer	0.000242	0.000847	CbGpPWpGaD
Levonorgestrel—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000241	0.000842	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—HRAS—thyroid cancer	0.000231	0.000806	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TCF7L1—thyroid cancer	0.00023	0.000802	CbGpPWpGaD
Levonorgestrel—CYP19A1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000229	0.000799	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000226	0.00079	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—TPR—thyroid cancer	0.000224	0.000784	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—SST—thyroid cancer	0.000223	0.000778	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PRKAR1A—thyroid cancer	0.000221	0.000772	CbGpPWpGaD
Levonorgestrel—AR—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.00022	0.00077	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CALCA—thyroid cancer	0.000214	0.000749	CbGpPWpGaD
Levonorgestrel—ESR1—Generic Transcription Pathway—PPARG—thyroid cancer	0.000213	0.000745	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—RXRA—thyroid cancer	0.000211	0.000737	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	0.000205	0.000715	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling by ERBB4—AKT1—thyroid cancer	0.000204	0.000712	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000201	0.000702	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.0002	0.000699	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CDK1—thyroid cancer	0.000194	0.000678	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000177	0.000618	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—PPARG—thyroid cancer	0.000175	0.000611	CbGpPWpGaD
Levonorgestrel—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	0.00017	0.000593	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—SLC5A5—thyroid cancer	0.000168	0.000587	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TSHR—thyroid cancer	0.000168	0.000587	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000165	0.000578	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—RXRA—thyroid cancer	0.000163	0.000568	CbGpPWpGaD
Levonorgestrel—SRD5A1—Metabolism—AKT1—thyroid cancer	0.000162	0.000567	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—MEN1—thyroid cancer	0.000158	0.000552	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000157	0.00055	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRG1—thyroid cancer	0.000156	0.000544	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000151	0.000526	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTCH1—thyroid cancer	0.000143	0.000499	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000142	0.000494	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—RXRA—thyroid cancer	0.000141	0.000493	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TERT—thyroid cancer	0.00014	0.000489	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000137	0.00048	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HIF1A—thyroid cancer	0.000134	0.000467	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—PPARG—thyroid cancer	0.000133	0.000466	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—SST—thyroid cancer	0.000131	0.000457	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CALCA—thyroid cancer	0.000126	0.00044	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000114	0.000399	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CDK1—thyroid cancer	0.000114	0.000398	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—BRAF—thyroid cancer	0.000111	0.000387	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—PPARG—thyroid cancer	0.000103	0.000359	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRG1—thyroid cancer	9.14e-05	0.000319	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PPARG—thyroid cancer	8.91e-05	0.000311	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TERT—thyroid cancer	8.21e-05	0.000287	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—CCND1—thyroid cancer	8.08e-05	0.000282	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HIF1A—thyroid cancer	7.85e-05	0.000274	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—PTEN—thyroid cancer	7.8e-05	0.000273	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTGS2—thyroid cancer	7.01e-05	0.000245	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—NRAS—thyroid cancer	6.96e-05	0.000243	CbGpPWpGaD
Levonorgestrel—PGR—Gene Expression—AKT1—thyroid cancer	6.91e-05	0.000242	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—TPR—thyroid cancer	6.55e-05	0.000229	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—BRAF—thyroid cancer	6.5e-05	0.000227	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	6.44e-05	0.000225	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—PTEN—thyroid cancer	6.12e-05	0.000214	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—KRAS—thyroid cancer	5.99e-05	0.000209	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—TP53—thyroid cancer	5.32e-05	0.000186	CbGpPWpGaD
Levonorgestrel—AR—Gene Expression—AKT1—thyroid cancer	5.27e-05	0.000184	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—HRAS—thyroid cancer	5.09e-05	0.000178	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.9e-05	0.000171	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—CCND1—thyroid cancer	4.74e-05	0.000166	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—PTEN—thyroid cancer	4.58e-05	0.00016	CbGpPWpGaD
Levonorgestrel—PGR—Signaling Pathways—AKT1—thyroid cancer	4.5e-05	0.000157	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—RXRA—thyroid cancer	4.12e-05	0.000144	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—NRAS—thyroid cancer	4.08e-05	0.000143	CbGpPWpGaD
Levonorgestrel—ESR1—Gene Expression—AKT1—thyroid cancer	4.06e-05	0.000142	CbGpPWpGaD
Levonorgestrel—CYP19A1—Metabolism—AKT1—thyroid cancer	3.52e-05	0.000123	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—KRAS—thyroid cancer	3.52e-05	0.000123	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—TP53—thyroid cancer	3.12e-05	0.000109	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—HRAS—thyroid cancer	2.99e-05	0.000104	CbGpPWpGaD
Levonorgestrel—ESR1—Signaling Pathways—AKT1—thyroid cancer	2.64e-05	9.22e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PPARG—thyroid cancer	2.6e-05	9.09e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.05e-05	7.15e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—PTEN—thyroid cancer	1.78e-05	6.24e-05	CbGpPWpGaD
Levonorgestrel—CYP3A4—Metabolism—AKT1—thyroid cancer	1.03e-05	3.59e-05	CbGpPWpGaD
